NCT07103018 2026-03-16
STRIKE-001
K36 Therapeutics, Inc.
Phase 1 Recruiting
Clinical Trials
20 trialsNCT06173362 2026-03-13
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
Phase 2 Recruiting
NCT05997615 2026-02-24
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT07406282 2026-02-12
Double-DARE
Bayer
Recruiting
NCT06631521 2026-02-05
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
AdventHealth
Phase 1 Recruiting
NCT05348876 2026-01-30
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Bayer
Phase 4 Recruiting
NCT06120491 2026-01-21
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT05519449 2026-01-20
ENGAGER-PSMA-01
Janux Therapeutics
Phase 1 Recruiting
NCT06592924 2026-01-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT07181122 2025-11-24
PRO-MIND
Ankara Etlik City Hospital
Recruiting
NCT07172685 2025-09-15
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
Qilu Hospital of Shandong University
Phase NA Recruiting
NCT05413421 2025-08-11
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
ORIC Pharmaceuticals
Phase 1 Recruiting
NCT04925648 2025-05-15
PICASSO
St Vincent's Hospital, Sydney
Phase 2 Recruiting
NCT06190899 2025-03-21
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc
Phase 1/2 Recruiting
NCT06652607 2025-03-12
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT04070209 2024-12-04
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Recruiting
NCT06575257 2024-08-28
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
Xijing Hospital
Phase 2 Recruiting
NCT05116475 2024-03-12
ALADDIN
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Recruiting
NCT06282588 2024-02-28
THUNDER
Cancer Research Antwerp
Phase 2/3 Recruiting